Question Bank › Nobody is coming: management describes a market

Nobody is coming: management describes a market it must build itself, and the first buyers have started paying

Calls Tested
466
Answered YES
8
Hit Rate
1.7%
rare by design

SOPHiA GENETICS SA (SOPH) — this company's answers

NO on the Q4 2021 call 2022-03-15 C
The model's full reasoning — Q4 2021 call → NOWe need to determine if management describes creating a market that does not yet exist, with conversion work succeeding. Look for evidence of market creation, education, changing habits, and recent paying conversions. In the transcript, Jurgi talks about the platform, network effects, and adoption. He mentions "land and expand" strategy, increasing utilization. He talks about new products like HRD, CarePath, DEEP-Lung-IV study. He mentions partnerships with GE, Ambry, AstraZeneca. He talks about onboarding customers, expanding network. Key points: They are a technology player, data-driven medicine. They talk about democratizing data-driven medicine. They mention that they are educating? They talk about "the practice of data driven medicine" and "helping healthcare professionals work together as a community." They mention that they are "unlocking data silos" and "helping healthcare professionals work together." They talk about "the ability to create insights from this data has led to an acceleration in our understanding of biology. However, much of this data is siloed preventing it from being fully leveraged for the benefit of patients." So they are addressing a problem of data silos, but is that market creation? They are providing a platform that requires customers to change their habits? They talk about "land and expand" and "increasing utilization within our existing customer base." They talk about "new customer adoption" and "network expansion." They mention "we are seeing solid growth with our clinical customer base." They talk about "onboarding clinical customers" and "expecting several signed agreements with Tier 1 institutions in the coming months." They talk about "we recently announced onboarding a leading Taiwanese genetic testing company called SOFIVA GENOMICS." They talk about "we recently signed new customers in Japan, South Korea, Singapore, and Hong Kong." So they are signing customers. But is the barrier about teaching, converting, changing habits? They talk about "the validation of our solution by this important customer is already underway." They talk about "we are encouraged with the momentum we see with users continuing to increase their consumption after experiencing the value of SOPHiA’s platform." That suggests that once customers use it, they see value and increase usage.

← Back to the full SOPH analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management describe the company as CREATING A MARKET THAT DOES NOT YET PROPERLY EXIST — that is, does management convey that the main obstacle in front of the business is not competition or price but the fact that the buyers themselves must first be TAUGHT, CONVERTED, QUALIFIED, OR HAVE THEIR OWN HABITS AND SYSTEMS CHANGED before they can buy at all — AND does management report that this conversion work has now begun to succeed with real paying buyers in the recent period? Answer YES when management's own words convey, in whatever form fits the business, ONE coherent situation with both halves present as a present-tense reality: (1) THE COMPANY IS DOING MARKET-CREATION WORK, NOT MARKET-SHARE WORK. Management describes effort spent on getting the world ready to buy, rather than on beating rivals for demand that already exists. Any genuine expression of this counts, and the form varies widely across industries — for example: management explaining that customers must be educated on a category, method, material, or approach they do not yet understand or trust; that buyers have to change an entrenched practice, workflow, standard, specification, protocol, or supply arrangement in order to adopt; that the company is spending its time training, certifying, demonstrating, running side-by-side comparisons, or working through customers' internal validation, testing, trial, or approval processes; that adoption is slow because decision-makers have never bought anything like this and there is no existing budget line, reimbursement path, permitting route, or procurement category for it; that the company is having to build the surrounding conditions of its own market — installers, prescribers, applicators, inspectors, dealers, code acceptance, industry awareness, or downstream capability — before volume can flow; or that the company's chief competitor is inertia, the status quo, or "the way it has always been done" rather than another vendor. Management should convey that this conversion problem, rather than winning a competitive bid, is what actually governs how fast the business grows. (2) THE CONVERSION IS NOW ACTUALLY WORKING, WITH MONEY BEHIND IT. Management points to concrete evidence from the recent period that the resistance is giving way and buyers are crossing over: converts who have moved from the old way to the company's way and are now purchasing; customers who completed their evaluation, testing, or internal approval and have begun ordering; adoption spreading from the earliest believers to more conventional or larger buyers; practices, specifications, or standards beginning to be written the company's way; or the pace of conversions picking up relative to what the company used to achieve. The evidence must be present-tense and paid — real orders, customers, deployments, or usage happening now — not merely interest, education efforts underway, or a large market management believes exists. The essence is ONE phenomenon: a company whose growth is gated by how fast it can change other people's minds and habits, which has just started to win that argument at scale. The industry, the entrenched habit being displaced, and the form of the conversion may vary widely. Answer NO if the company competes for demand that plainly already exists — bidding, winning share, out-selling rivals, or serving an established buying pattern — however well it is doing. NO if management merely asserts a large addressable market, a superior product, or that customers "just need to see it," without describing an adoption barrier of habit, understanding, qualification, or established practice that must be overcome first. NO if the education, trialing, or qualification work is described with nothing yet converting into paying business — pilots without orders, interest without commitment, a market being "developed" with no crossings to point to. NO if the conversion described is chiefly the company's own customers upgrading to its newer product generation rather than outsiders changing their existing practice. NO if the barrier described is purely a pending external approval or a single regulatory gate with no buyer-behavior change involved. NO if management is chiefly explaining that adoption has stalled, slowed, or proven harder than expected with no recent progress. NO if the idea appears only in an analyst's question or characterization that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
CALX Calix, Inc. Q1 2023 2023-04-20 C+
TMCI Treace Medical Concepts, Inc. Q2 2022 2022-08-13 B+
EXFY Expensify, Inc. Q2 2022 2022-08-12 D
HLNE Hamilton Lane Incorporated Q1 2023 2022-08-02 C+
SGRY Surgery Partners, Inc. Q2 2022 2022-08-02 B+
ALKS Alkermes plc Q3 2018 2018-10-23 C
ILMN Illumina, Inc. Q1 2018 2018-04-24 A
PCRX Pacira BioSciences, Inc. Q4 2017 2018-02-28 C

How the model reasoned

ILMN · Q1 2018 → YESThe question is whether management describes the company as creating a market that doesn't yet properly exist, where the main obstacle is teaching/converting buyers, changing their habits, and that th...YES The transcript shows management framing Illumina's growth as market creation in the "earliest stages of the genomics journey," where the core obstacle is buyer education, habit change, and qualification rather than competing for existing demand. They describe heavy investment in studies (Harvard Pilgrim NIPT, MiSeq rugged, UK Biobank, 100k Genomes) to generate clinical/economic evidence for payers and physicians, regulatory progress (CMS NCD, FDA 23andMe BRCA approval), and expanding reimbursement paths. This is explicitly positioned as overcoming inertia and entrenched practices ("the way it has always been done") before volume flows.
EXFY · Q2 2022 → YESThe question is whether management describes the company as creating a market that doesn't yet properly exist, with both market-creation work and successful conversion with paying buyers. YES The transcript shows David Barrett describing the SMB expense-management market as "largely untouched" with "hundreds of millions of businesses" where "virtually none of them do anything," positioning Expensify as the first to introduce concepts like real-time expense scanning and pre-accounting through ExpensiCon to educate and change accounting-industry habits. This frames the core obstacle as buyer conversion and habit change rather than direct rivalry. He contrasts this with competitors retreating to enterprise sales due to defaults and cost pressures, while Expensify's bottom-up model and Free Plan enable early-stage onboarding.
SGRY · Q2 2022 → YESThe question is whether management describes the company as creating a market that doesn't yet properly exist, where the main obstacle is teaching/converting buyers, changing their habits, and that th...YES The transcript shows management framing the core growth driver as a site-of-care shift that requires buyers (physicians, payers, patients) to change entrenched habits and systems: physicians must be recruited and trained to perform procedures in ASCs rather than hospitals; payers must adopt value-based incentives and capitated models to move volume 5-figure discounts; patients must accept lower-cost, high-quality outpatient settings. This is presented as the primary obstacle to faster growth, not competitive bidding for already-existing demand.

More from the question bank

Insulated through the downturnThe bridge is already builtManagement volunteers specific, checkable nuScarcity of the company's own outputThe company is being paid to solve a problemBet-the-company financing already spent on hAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.